NASDAQ: DCTHDelcath Systems Inc Stock
$4.70+0.22 (+4.91%)
Updated Apr 18, 2024
DCTH Price
$4.70
Fair Value Price
-$3.87
Market Cap
$115.32M
52 Week Low
$2.25
52 Week High
$7.99
P/E
-1.6x
P/B
7.31x
P/S
32.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.07M
Earnings
-$47.68M
Gross Margin
69.2%
Operating Margin
-2,239.18%
Profit Margin
-2,308.9%
Debt to Equity
1.45
Operating Cash Flow
-$31M
Beta
1.16
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
DCTH Overview
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. The firm's lead candidates, Melphalan Hydrochloride for Injection and the Delcath Hepatic Delivery System are designed to administer high-dose chemotherapy to the liver while controlling side effects. The company was founded in 1988 and is based in Queensbury, NY.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DCTH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DCTH ($4.70) is overvalued by 221.47% relative to our estimate of its Fair Value price of -$3.87 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DCTH ($4.70) is not significantly undervalued (221.47%) relative to our estimate of its Fair Value price of -$3.87 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DCTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DCTH due diligence checks available for Premium users.
Be the first to know about important DCTH news, forecast changes, insider trades & much more!
DCTH News
Valuation
DCTH fair value
Fair Value of DCTH stock based on Discounted Cash Flow (DCF)
Price
$4.70
Fair Value
-$3.87
Undervalued by
221.60%
DCTH ($4.70) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DCTH ($4.70) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DCTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DCTH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.6x
Industry
28.61x
Market
41.33x
DCTH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.31x
Industry
3.63x
DCTH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DCTH's financial health
Profit margin
Revenue
$539.0k
Net Income
-$11.1M
Profit Margin
-2,066%
DCTH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
DCTH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$38.6M
Liabilities
$22.8M
Debt to equity
1.45
DCTH's short-term assets ($37.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DCTH's short-term assets ($37.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DCTH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DCTH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.2M
Investing
-$19.7M
Financing
$1.0k
DCTH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DCTH vs Medical Device Stocks
Delcath Systems Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.